BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Prognosis
30 results:

  • 1. CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for pai-1.
    Durlanik S; Fundel-Clemens K; Viollet C; Huber HJ; Lenter M; Kitt K; Pflanz S
    Sci Rep; 2021 Jul; 11(1):14849. PubMed ID: 34290311
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Integrative analysis of the common genetic characteristics in ovarian cancer stem cells sorted by multiple approaches.
    Zhang X; Su Y; Wu X; Xiao R; Wu Y; Yang B; Wang Z; Guo L; Kang X; Wang C
    J Ovarian Res; 2020 Sep; 13(1):116. PubMed ID: 32977853
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. pai-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
    Peng Y; Kajiyama H; Yuan H; Nakamura K; Yoshihara M; Yokoi A; Fujikake K; Yasui H; Yoshikawa N; Suzuki S; Senga T; Shibata K; Kikkawa F
    Cancer Lett; 2019 Feb; 442():181-192. PubMed ID: 30429105
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
    Kazarian A; Blyuss O; Metodieva G; Gentry-Maharaj A; Ryan A; Kiseleva EM; Prytomanova OM; Jacobs IJ; Widschwendter M; Menon U; Timms JF
    Br J Cancer; 2017 Feb; 116(4):501-508. PubMed ID: 28081538
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Biomarkers in Breast cancer: Where Are We and Where Are We Going?
    Duffy MJ; Walsh S; McDermott EW; Crown J
    Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
    Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
    Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
    Chen S; Tai H; Tong X; Wang J; Yang F; Yang Y; Yiqin O
    J Obstet Gynaecol Res; 2014 Sep; 40(9):2058-65. PubMed ID: 25181626
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.
    Battista MJ; Mantai N; Sicking I; Cotarelo C; Weyer V; Lebrecht A; Solbach C; Schmidt M
    Oncol Rep; 2014 May; 31(5):2213-9. PubMed ID: 24627004
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
    Gershteĭn ES; Kushlinskiĭ NE
    Vestn Ross Akad Med Nauk; 2013; (5):16-27. PubMed ID: 24000664
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
    Ren F; Shi H; Zhang G; Zhang R
    J Exp Clin Cancer Res; 2013 Aug; 32(1):60. PubMed ID: 23988121
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.
    Serce NB; Boesl A; Klaman I; von Serényi S; Noetzel E; Press MF; Dimmler A; Hartmann A; Sehouli J; Knuechel R; Beckmann MW; Fasching PA; Dahl E
    BMC Cancer; 2012 Dec; 12():597. PubMed ID: 23236990
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma.
    Komiyama S; Aoki D; Saitoh E; Komiyama M; Udagawa Y
    Eur J Gynaecol Oncol; 2011; 32(6):611-4. PubMed ID: 22335020
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Ligand-dependent EGFR activation induces the co-expression of IL-6 and pai-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
    Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
    Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells.
    Henic E; Noskova V; Høyer-Hansen G; Hansson S; Casslén B
    Int J Gynecol Cancer; 2009 Feb; 19(2):214-22. PubMed ID: 19395996
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Expression and clinical significance of uPA and pai-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
    Whitley BR; Beaulieu LM; Carter JC; Church FC
    Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and pai-1 in primary ovarian carcinoma.
    Dorn J; Harbeck N; Kates R; Magdolen V; Grass L; Soosaipillai A; Schmalfeldt B; Diamandis EP; Schmitt M
    Biol Chem; 2006 Aug; 387(8):1121-8. PubMed ID: 16895483
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
    Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
    Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.